𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specificity of the phase I trial for cytotoxic drugs in oncology

✍ Scribed by JP Armand; M. Klink-Alakl; G. Recondo; M. de Forni

Book ID
115273805
Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
443 KB
Volume
4
Category
Article
ISSN
0767-3981

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

New Adaptive Method for Phase I Trials i
New Adaptive Method for Phase I Trials in Oncology
✍ Meille, C; Gentet, JC; Barbolosi, D; AndrΓ©, N; Doz, F; Iliadis, A πŸ“‚ Article πŸ“… 2007 πŸ› Nature Publishing Group 🌐 English βš– 593 KB
Continual reassessment methods in phase
Continual reassessment methods in phase I trials of the combination of two drugs in oncology
✍ Andrew Kramar; Anne Lebecq; Emmanuel Candalh πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

Most phase I trials in oncology use standard methods for treating successive groups of patients with increasing doses in order to determine the maximum tolerated dose (MTD). These methods have been criticized because they treat many patients at suboptimal dose levels, and do not provide an accurate

Phase I trials in paediatric oncology β€”
Phase I trials in paediatric oncology β€” the European perspective
✍ E. J. Estlin; S. Ablett; D. R. Newell; I. J. Lewis; L. Lashford; A. D. J. Pearso πŸ“‚ Article πŸ“… 1996 πŸ› Springer US 🌐 English βš– 881 KB

The current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of cu